IL17A and congenital rubella syndrome: Sarmiento-Monroy et al. suggest that since cytokines released by Th17 in SARS-CoV-2 infection are hazardous in the context of CRS and ARDS, the usage of biological therapies targeting IL-23/IL-17 axis could be potentially beneficial in those scenarios [68].